SCHEDULE: OS Therapies: Major Shareholder Trims Stake

Shalom Auerbach and Einodmil LLC updated their beneficial ownership in OS Therapies Inc, reporting a slight reduction in Einodmil's stake through an open market sale.

Summary

• Shalom Auerbach and Einodmil LLC filed Amendment No. 4 to their Schedule 13D regarding their beneficial ownership in OS Therapies Inc.
• As of July 29, 2025, Shalom Auerbach beneficially owns 2,677,570 shares, representing approximately 8.5% of the Issuer's outstanding Common Stock.
• As of July 29, 2025, Einodmil LLC beneficially owns 2,654,199 shares, representing approximately 8.4% of the Issuer's outstanding Common Stock.
• On July 3, 2025, Einodmil LLC sold 10,000 shares of Common Stock on the open market at approximately $2.10 per share, generating proceeds of approximately $20,695.
• The beneficial ownership percentages are based on 31,624,076 shares of Common Stock outstanding as of July 29, 2025, as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant beneficial owner reducing their stake, which can be interpreted as a lack of conviction or a move to realize gains/losses. While the amount sold is small relative to total holdings, it's a divestment.

Negatives

• A significant beneficial owner, Einodmil LLC, reduced its stake by selling 10,000 shares, indicating a partial divestment.

Risks

• Potential for further sales by significant shareholders, which could exert downward pressure on the stock price.
• Reduced confidence from a major investor, potentially signaling concerns about future performance or valuation.

Future Outlook

This Schedule 13D amendment does not provide any forward-looking statements or guidance regarding the Issuer's future operations or financial performance.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by a significant shareholder and does not provide information directly related to broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sectors.

Comparison to Industry Standards

• This filing is a regulatory disclosure of beneficial ownership changes and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.

Stakeholder Impact

• Shareholders: The sale by a significant beneficial owner might lead to negative sentiment or increased selling pressure, potentially impacting share price.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for OS Therapies Inc. or the reporting persons beyond the regulatory disclosure.

Key Dates

Recommendation

While a significant shareholder reduced their stake, the sale of 10,000 shares is a relatively small portion of their total holdings (2.65M shares). This could be for various reasons, including portfolio rebalancing or liquidity needs, rather than a fundamental negative view of the company. Without further information on the company's operations or financial performance, a 'hold' recommendation is appropriate, advising investors to monitor future filings and company developments closely.

Keywords

OS Therapies Inc, Common Stock, Schedule 13D, Beneficial Ownership, Shalom Auerbach, Einodmil LLC, Share Sale, SEC Filing, Institutional Investor, Equity Stake